TACSTD2 and neoplasm: In mesenchymal-like tumor cells, TROP-2 sustains oncogenic signaling through PI3K/AKT and MAPK pathways independently of traditional hormone receptors, promoting survival, angiogenesis, and immune evasion [25–27].